Intraperitoneal amino acids: a therapy whose time has come?
In regard to the question posed in the title of this review, the answer is mixed. IPN is possible today but only on a limited basis and at high cost with uncertain benefit. A 1.1% amino acid dialysis solution for IPAA therapy is available in several European countries but has not yet been approved for use in the United States. When it becomes more widely available, IPAA should become an important tool, along with other types of therapy, for use in the maintenance of good nutritional status in PD patients.
Jones
M R
MR
Renal Division, Baxter Healthcare Corporation, McGaw Park, Illinois 60085-6730, USA.
D000596:Amino Acids / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D001068:Feeding and Eating Disorders / Q000209:etiology; D006801:Humans; D007274:Injections, Intraperitoneal; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D011502:Protein-Energy Malnutrition / Q000628:therapy*; D014511:Uremia / Q000209:etiology; D014883:Water-Electrolyte Imbalance / Q000209:etiology
D000596:Amino Acids